公开(公告)号：US11357801B2

公开(公告)日：2022-06-14

申请号：US16306240

申请日：2017-06-14

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： James Adams ,  Dae-Wook Kang ,  Rosa Krajmalnik-Brown

IPC: A61K35/741 ,  A61K35/745 ,  A61K35/74

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.

公开(公告)号：US11202808B2

公开(公告)日：2021-12-21

申请号：US16235635

申请日：2018-12-28

Applicant: Arizona Board of Regents on behalf of Arizona State University ,  Regents of the University of Minnesota ,  Finch Therapeutics Holdings LLC

Inventor： James Adams ,  Rosa Krajmalnik-Brown ,  Dae-Wook Kang ,  Michael J. Sadowsky ,  Alexander Khoruts ,  Thomas J. Borody

IPC: A61P1/00 ,  A61K35/741 ,  A61K45/06 ,  A61K38/08 ,  A61K38/14 ,  A61K35/74 ,  A61K35/12

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

公开(公告)号：US20250034656A1

公开(公告)日：2025-01-30

申请号：US18714217

申请日：2022-11-30

Applicant: Arizona Board of Regents on Behalf of Arizona State University

Inventor： Rosa Krajmalnik-Brown ,  James Adams ,  Khemlal Nirmalkar

IPC: C12Q1/689

Abstract: The present disclosure relates to methods for monitoring effectiveness of a treatment of an autism spectrum disorder (ASD) by analyzing an ASD patient's gut microbiota based on stool samples. Also provided are software for implementing the methods, and kits for performing the methods.